Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Genzyme Updates Cerezyme Supply; Responds to Sanofi Bid
- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
Clinical Trials News- Clinilabs Selected for a Phase I/II Study of HIV Vaccine
- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
Blogroll
-
Meta
Tag Archives: Research and development
Merck to Close Eight Plants
Image by Getty Images via @daylife
Over the next two years, Merck will shut down eight manufacturing plants, as well as eight research sites, as part of the ongoing Schering-Plough merger process. The company said in a statement that the various site exits will help “create a flexible R&D organization.”
Taking a page out of Pfizer’s book [...]
Posted in Strategy Also tagged business, Canada, Factory, Infectious disease, Merck, Schering Plough, South America 3 Comments
Takeda Launches New Plan, Cuts US Jobs
Image via Wikipedia
The Japanese are taking a play from the US pharmaceutical industry’s rulebook and restructuring itself under the auspices of a fun catch phrase: “Transformation for a New Takeda.”
The punch line, however, isn’t too funny.
According to a two-year mid-range plan announced yesterday, Takeda will cut about 1,400 positions in the US to fend off [...]
BIO Convention: Potemkin Pavilions and the Power of NICE
Image by Getty Images via Daylife
Last week’s annual meeting of BIO in Chicago once again proved illustrative in showcasing the high profile that governments now plays as the biotech sector’s chief advocate. While private venture capitalists confined themselves to the margins of the meeting, the Convention hall was bursting at the seams with host [...]
Posted in Biotech Also tagged Biotechnology, business, Health care, Inter American Development Bank, Pharmaceutical drug, venture capital, World Bank Leave a comment
AstraZeneca to Slash 8,000 More Jobs (Updated 2/3/10)
Last year, AstraZeneca announced the elimination of some 15,000 jobs. Last Thursday, the London-based company revealed that it plans to lay off another 8,000 by 2014—this despite global revenue growth of 4 percent for 2009.
Much of the drive for this addition labor sculpting stems from AZ’s desire to streamline its R&D; the company will focus [...]
Posted in Strategy Also tagged AstraZeneca, business, Company, David Brennan, Employment, GlaxoSmithKline, layoffs, London 1 Comment

Study: Future of Personalized Medicine